CML
Conference Coverage
Half of CML patients can stop TKI therapy, study suggests
© Todd Buchanan 2016 SAN DIEGO—Updated results of the EURO-SKI trial support the idea that certain chronic myeloid leukemia (CML) patients can...
Article
VIDEO: Half-dose TKI safe, cost-effective in CML in stable remission
SAN DIEGO – For some patients with solid stable remissions, halving the TKI dose or even stopping therapy altogether appears to be safe.
Conference Coverage
Halving the TKI dose safe, cost effective in CML patients with stable remissions
SAN DIEGO - For some CML patients with solid, stable remissions, halving their dose of a tyrosine kinase inhibitor – or even stopping therapy...
News
FDA grants full approval for ponatinib
Photo from Business Wire The US Food and Drug Administration (FDA) has granted full approval for the kinase inhibitor ponatinib (Iclusig®) and...
From the Journals
Secondary reference panel expands access for CML monitoring
A cell-based BCR-ABL1 secondary reference panel traceable to the World Health Organization BCR-ABL1 International Genetic Reference Panel – with...
News
Two-drug combination targets LSCs in CML
Image by Difu Wu Targeting a pair of transcription factors might improve the treatment of chronic myeloid leukemia (CML), according to...
News
Compound could treat a range of blood cancers
Image by Ed Uthman A new compound has shown promise for treating hematologic malignancies and other cancers, according to preclinical research...
News
Legislators question price of leukemia drug
Photo from Business Wire A pair of US legislators are questioning why ARIAD Pharmaceuticals, Inc. has increased the price of its leukemia drug...
From the Journals
STIM1 long-term follow-up confirms imatinib discontinuation safety
Imatinib discontinuation is safe in patients with chronic myeloid leukemia who have sustained deep molecular response with no late molecular...
From the Journals
Cost may hinder timely TKI initiation for CML
Nearly a third of Medicare beneficiaries with chronic myeloid leukemia did not initiate tyrosine kinase inhibitor therapy within 6 months of...
Conference Coverage
Doc offers advice on choosing a frontline TKI
Photo by D.